两种药物联合治疗原发性免疫性血小板减少症的效果分析

Effects of Two Drugs on the Treatment of Primary Immune Thrombocytopenia

目的分析重组人血小板生成素联合糖皮质激素治疗原发性免疫性血小板减少症临床效果。方法选取2015年7月—2017年8月本院收治的68例原发性免疫性血小板减少症患者作为研究对象,随机将其分成两组,参照组采用糖皮质激素进行治疗,观察组采用重组人血小板生成素联合糖皮质激素进行治疗,对比两组患者的临床效果。结果观察组患者的治疗有效率为94.12%,高于参照组的73.53%(P<0.05);观察组患者治疗后各项数据均优于参照组(P<0.05)。结论重组人血小板生成素联合糖皮质激素治疗原发性免疫性血小板减少症可有效并快速的恢复患者血小板指标,治疗有效率较高。

Objective To analyze the clinical effect of recombinant human thrombopoietin combined with glucocorticoid in the treatment of primary immune thrombocytopenia. Methods From July 2015 to August 2017, 68 patients with idiopathic thrombocytopenia admitted to our hospital were selected as a research object,they were randomly divided into two groups, the control group with glucocorticoid treatment, the observation group using recombinant human platelet bone formation hormone combined with glucocorticoid treatment, compared the clinical effect of two groups of patients. Results The effective rate of treatment was 94.12% in the observation group, which was higher than 73.53% in the control group（P﹤0.05）. All the data of the observation group were better than the control group（P﹤ 0.05）. Conclusion Recombinant human thrombopoietin combined with glucocorticoid to treat primary immune thrombocytopenia can effectively and rapidly restore the platelet index of patients, and the treatment efficiency is high.